Myeloproliferative Neoplasm

WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...

BURLINGTON, Mass., July 6, 2026 PharmaEssentia Corporation announced that its wholly owned Canadian subsidiary, FORUS Therapeutics Inc., has received...